Westminster, CO — March 31, 2020 — Flagship Biosciences, providers of expert tissue data insights, today announced that Geoff Metcalf, MBA, PMP, will join its executive team as Vice President Clinical Diagnostics. Geoff brings 25 years of experience in developing and...
Elliott Ergon a Research and Development Process Engineer at Flagship Biosciences. He studied chemical and biological engineering at the University of Colorado – Boulder and received his BS. Elliott shared what led him to his work in science. “Growing up I always had...
Michael Argyres, MD, is Flagship’s Director of Pathology, diagnostic biomarkers. Mike received his BA at UC Berkeley in molecular biology, his MD at the Medical College of Wisconsin, did his pathology residency at the University of Colorado, a surgical pathology...
Flagship scientist Chuck Caldwell received his PhD in Biological Engineering at the University of Missouri and BS, Biological Engineering, also at the University of Missouri, and did postdoctoral studies at the University of Colorado. He recently shared some of his...
Spokane, WA, and Westminster, CO – September 26, 2019 – Gestalt Diagnostics and Flagship Biosciences today announced their collaboration in the development of an integrated workflow for pathologists to access Flagship’s Image Analysis services for digital images to...
Spokane, WA, and Westminster, CO – September 26, 2019 – Gestalt Diagnostics and Flagship Biosciences today announced their collaboration in the development of an integrated workflow for pathologists to access Flagship’s Image Analysis services for digital images to...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
PUBLICATIONS
Artificial intelligence (AI) systems for pathology may appear to compete with manual pathology, as they enable the assessment of thousands of cells and application of complex scoring schemes beyond the capacity of a human pathologist. However, this technology...
CIOReview named Flagship Biosciences “Company of the Year,” as part of the publication’s 2018 20 Most Promising Pharma & Life Sciences Tech Solution Providers industry review. “The ease of leveraging Flagship’s powerful solution is yet another massive...
Key Concepts: Pathological interpretations applied to PD-L1 IHC as a response biomarker are becoming more complex, going beyond simple tumor proportion score (TPS) and requiring more complex diagnostic algorithms that evaluate the role of PDL1 expression in tumor...
EVENTS
Visit Flagship at SITC | Booth #818.November 8-12, 2022.Stop by our booth to meet our new CSO Tom Turi, Ph.D., and talk with us about how we can partner with you for end-to-end biomarker support. Come learn about our new services, and pick up a map of our favorite...
Visit Flagship at World CB & CDx | Booth #4. Boston, MA | September 26-29, 2022. Stop by our booth to talk with us about how we can partner with you for end-to-end biomarker support and see our latest data. Assay development and validation Clinical trial support...
Visit Flagship at AACR | Booth #1554. April 8-13, 2022. Stop by our booth to talk with us about how we can partner with you for end-to-end biomarker support, see our latest data from this year’s featured posters, and pick up a map of our favorite NOLA eateries. Assay...